Cargando…

Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study

As a chronic autoimmune disease, systemic lupus erythematosus (SLE) primarily affects young women and does not discriminate against any particular organs. In December 2019, coronavirus disease 2019 (COVID-19) spread worldwide, with many speculations of cardiac involvement in the pathogenesis of infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yost, Connor, Vercillo, Darin, Abuqare, Abdulelah, Yost, Mckenna b, Love, Avery N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202560/
https://www.ncbi.nlm.nih.gov/pubmed/37223159
http://dx.doi.org/10.7759/cureus.37988
_version_ 1785045451841470464
author Yost, Connor
Vercillo, Darin
Abuqare, Abdulelah
Yost, Mckenna b
Love, Avery N
author_facet Yost, Connor
Vercillo, Darin
Abuqare, Abdulelah
Yost, Mckenna b
Love, Avery N
author_sort Yost, Connor
collection PubMed
description As a chronic autoimmune disease, systemic lupus erythematosus (SLE) primarily affects young women and does not discriminate against any particular organs. In December 2019, coronavirus disease 2019 (COVID-19) spread worldwide, with many speculations of cardiac involvement in the pathogenesis of infection. Moreover, in cases where cardiac symptoms were described, they consisted solely of chest pain or a general deterioration in health if the patient presented with pleural effusion or pericardial effusion. Our patient, a 25-year-old Hispanic woman, initially complained of chest pain, cough, and shortness of breath. After being admitted, she noticed growing dyspnea and mild discomfort on the right side of her chest. The patient had both SLE and COVID-19 and had developed pleural and pericardial effusions. After two days in culture, nothing had grown from the fluid samples. In addition, measures of brain natriuretic peptide and total creatine kinase fell within the normal range. Considering the investigational findings, pericardiocentesis was performed. After the procedure, the patient's condition improved, and she was discharged. The patient continued taking CellCept® 1,500 mg and Plaquenil 200 mg and started taking colchicine. Her daily prednisone dose was increased to 40 milligrams. She felt well initially; however, after two weeks of follow-up, the pericardial effusion recurred, and pericardiocentesis was performed again. The patient was discharged in stable condition after a two-day hospital stay. After treatment of both initial and recurrent effusions, the patient’s cardiac symptoms were resolved, and blood pressure became stable. We hypothesize that there may be other unreported cases of COVID-19-related viral pericarditis, pericardial effusion, and pericardial tamponade that could be caused by a combination of COVID-19 and a pre-existing condition, mainly autoimmune disorders. Due to the lack of clarity surrounding typical COVID-19 manifestations, it is crucial to record all cases of this unique illness and analyze any increased incidence of pericarditis, pericardial effusion, and pericardial tamponade in the public.
format Online
Article
Text
id pubmed-10202560
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102025602023-05-23 Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study Yost, Connor Vercillo, Darin Abuqare, Abdulelah Yost, Mckenna b Love, Avery N Cureus Cardiology As a chronic autoimmune disease, systemic lupus erythematosus (SLE) primarily affects young women and does not discriminate against any particular organs. In December 2019, coronavirus disease 2019 (COVID-19) spread worldwide, with many speculations of cardiac involvement in the pathogenesis of infection. Moreover, in cases where cardiac symptoms were described, they consisted solely of chest pain or a general deterioration in health if the patient presented with pleural effusion or pericardial effusion. Our patient, a 25-year-old Hispanic woman, initially complained of chest pain, cough, and shortness of breath. After being admitted, she noticed growing dyspnea and mild discomfort on the right side of her chest. The patient had both SLE and COVID-19 and had developed pleural and pericardial effusions. After two days in culture, nothing had grown from the fluid samples. In addition, measures of brain natriuretic peptide and total creatine kinase fell within the normal range. Considering the investigational findings, pericardiocentesis was performed. After the procedure, the patient's condition improved, and she was discharged. The patient continued taking CellCept® 1,500 mg and Plaquenil 200 mg and started taking colchicine. Her daily prednisone dose was increased to 40 milligrams. She felt well initially; however, after two weeks of follow-up, the pericardial effusion recurred, and pericardiocentesis was performed again. The patient was discharged in stable condition after a two-day hospital stay. After treatment of both initial and recurrent effusions, the patient’s cardiac symptoms were resolved, and blood pressure became stable. We hypothesize that there may be other unreported cases of COVID-19-related viral pericarditis, pericardial effusion, and pericardial tamponade that could be caused by a combination of COVID-19 and a pre-existing condition, mainly autoimmune disorders. Due to the lack of clarity surrounding typical COVID-19 manifestations, it is crucial to record all cases of this unique illness and analyze any increased incidence of pericarditis, pericardial effusion, and pericardial tamponade in the public. Cureus 2023-04-22 /pmc/articles/PMC10202560/ /pubmed/37223159 http://dx.doi.org/10.7759/cureus.37988 Text en Copyright © 2023, Yost et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Yost, Connor
Vercillo, Darin
Abuqare, Abdulelah
Yost, Mckenna b
Love, Avery N
Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title_full Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title_fullStr Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title_full_unstemmed Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title_short Pleural and Pericardial Effusion With COVID-19 and Systemic Lupus Erythematosus and Its Recurrence: A Case Study
title_sort pleural and pericardial effusion with covid-19 and systemic lupus erythematosus and its recurrence: a case study
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202560/
https://www.ncbi.nlm.nih.gov/pubmed/37223159
http://dx.doi.org/10.7759/cureus.37988
work_keys_str_mv AT yostconnor pleuralandpericardialeffusionwithcovid19andsystemiclupuserythematosusanditsrecurrenceacasestudy
AT vercillodarin pleuralandpericardialeffusionwithcovid19andsystemiclupuserythematosusanditsrecurrenceacasestudy
AT abuqareabdulelah pleuralandpericardialeffusionwithcovid19andsystemiclupuserythematosusanditsrecurrenceacasestudy
AT yostmckennab pleuralandpericardialeffusionwithcovid19andsystemiclupuserythematosusanditsrecurrenceacasestudy
AT loveaveryn pleuralandpericardialeffusionwithcovid19andsystemiclupuserythematosusanditsrecurrenceacasestudy